TL-895 + ruxolitinib

The combination of **TL-895 + ruxolitinib** is an investigational therapeutic approach for treating myelofibrosis, a bone marrow disorder. **TL-895** is a highly potent, selective, orally available covalent small molecule inhibitor of Bruton's tyrosine kinase (BTK) and bone marrow tyrosine kinase X-linked (BMX)[2]. **Ruxolitinib** is a well-established oral inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2)[1][2]. The rationale for combining these drugs is to augment the effect of JAK inhibition by targeting additional pro-survival and pro-inflammatory signaling pathways in malignant cells and the tumor microenvironment, potentially resulting in deeper and more durable responses in myelofibrosis, especially in patients with suboptimal response to ruxolitinib alone[2][3]. TL-895 is still in clinical development and not approved for routine use; ruxolitinib is approved and widely used for myelofibrosis.

Other names

TL-895 + ruxolitinib